Skip to main content
. 2021 Dec 7;8(6):ENEURO.0341-21.2021. doi: 10.1523/ENEURO.0341-21.2021

Figure 4.

Figure 4.

Effects of intra-lOFC infusions of the 5-HT2C receptor agonist RS 102221 in (A) risk-preferring animals (n =9) and (B) optimal decision-makers (n =9) on P1–P4 choice. Antagonism of the 5-HT2C receptor in the lOFC decreased P3 choice and increased P1 choice on the crGT in risk-preferring rats. Data are expressed as mean ± SEM; *p < 0.05 compared with vehicle.